SCHEMBL2091120

SCHEMBL2091120

COCCCCc1nccs1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.39
TLR7 Q9NYK1 1/20 0.35
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
CYP3A4 P08684 1/20 0.33
KDM1A O60341 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LTA4H P09960 1/20 0.33
SLC6A3 Q01959 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GLS O94925 1/20 0.33
PLA2G4A P47712 1/20 0.32
LMNA P02545 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12811609 0.94 FDPS (0.40) FDPSTLR7TSHRMAPK1CHRM2
SCHEMBL1276911 0.86
SCHEMBL2091117 0.81 FDPS (0.35) FDPSTSHRCHRM2CHRM1CHRM3
SCHEMBL9256303 0.81 PLA2G4A (0.33) FDPSCHRM2CHRM1CHRM3LTA4H
SCHEMBL244221 0.79 PLA2G4A (0.41) FDPSTLR7SLC6A3L3MBTL1PLA2G4A
SCHEMBL5543804 0.77 FDPS (0.36) FDPSCHRM2CHRM1CHRM3LTA4H
SCHEMBL5543803 0.77 FDPS (0.36) FDPSCHRM2CHRM1CHRM3LTA4H
SCHEMBL4584899 0.77 PLA2G4A (0.43) FDPSTLR7L3MBTL1PLA2G4AALDH1A1
SCHEMBL4584005 0.77 PLA2G4A (0.43) FDPSTLR7L3MBTL1PLA2G4AALDH1A1
SCHEMBL4584723 0.77 PLA2G4A (0.43) FDPSTLR7L3MBTL1PLA2G4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 FDPS 1113/4885TLR7 528/4885TSHR 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.